Sunesis Core Technology Sample Clauses

Sunesis Core Technology. Sunesis shall have the right to control the preparation, filing, prosecution and maintenance of patent applications and patents directed to Sunesis Core Technology using patent counsel of Sunesis’s choice, provided that such decisions made by Sunesis in the preparation, filing, prosecution, and maintenance of such patents and patent applications shall be reasonable and Sunesis shall employ reasonable efforts not to substantially negatively impact Millennium’s rights hereunder.
Sample 1Sample 2Sample 3See All (10)
AutoNDA by SimpleDocs
Sunesis Core Technology. All right, title and interest in and to the Sunesis Core Technology, and in any improvements to Sunesis Core Technology (i) made using or derived from Sunesis Core Technology, and (ii) made by or under authority of either Party or its Affiliates during the Term of this Agreement, shall, as between the Parties, be owned solely by Sunesis. Biogen Idec hereby assigns to Sunesis all of its and its Affiliates rights in and to such inventions and improvements made using or derived from Sunesis Core Technology (including all patent and other intellectual property rights therein), subject to the licenses granted to Biogen Idec under Article 6.
Sample 1Sample 2Sample 3See All (6)
Sunesis Core Technology. Sunesis No. Serial No. Title Status SU-100 US 09/105,372 Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to Biological Target Molecules Granted U.S. Patent No. 6,335,155 SU-100 D1C1 US 10/043,833 Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to Biological Target Molecules Granted as US Patent No. 6,811,966 { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXHIBIT 1.41 { * } { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXHIBIT 2.7.1 Phase II Drug Compounds { * } { * } = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE NOTATION “[RESERVED]” IS ORIGINAL, IS CURRENTLY IN THE DOCUMENT AND DOES NOT REFLECT INFORMATION REDACTED PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. EXHIBIT 3.5 Reverted Products
Sample 1Sample 2See All (4)
Sunesis Core Technology. All right, title and interest in and to the Sunesis Core Technology, and in any inventions or improvements made by or under authority of either Party or its Affiliates during the term of this Agreement relating to Sunesis Core Technology, shall, as between the Parties, be owned solely by Sunesis. Biogen hereby assigns to Sunesis all of its and its Affiliates rights in and to such inventions and improvements relating to Sunesis Core Technology (including all patent and other intellectual property rights therein).
Sample 1
Sunesis Core Technology. Section 1. UC Patents within the Sunesis Core Technology. Sunesis No. Serial No. Title Status UC-100 US 09/049,754 Pharmacophore Recombination For the Identification of Small Molecule Drug Lead Compounds Issued as U.S. Patent No. 6,344,330 UX-000 XX 00000/00 Xxxxxxxxxxxxx Recombination For the Identification of Small Molecule Drug Lead Compounds Issued as AU Patent No. 759327 [*] [*] [*] pending [*] [*] [*] pending [*] [*] [*] pending [*] [*] [*] pending [*] [*] [*] pending [*] [*] [*] pending [*] [*] [*] pending [*] [*] [*] pending [*] [*] [*] pending [*] Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Sample 1
Sunesis Core Technology. Subject to the terms and conditions of this Agreement, Sunesis hereby grants to JJPRD a worldwide, non-exclusive license under the Sunesis Patent Rights as reasonably necessary to make, have made, use, import, offer for sale, sell, and have sold Collaboration Compounds and JJPRD Derivative Compounds, alone or as incorporated into a Product, for any purpose.
Sample 1

Related to Sunesis Core Technology

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Licensed Technology The term “Licensed Technology” shall mean the Licensed Patent Rights, Licensed Know-How and Licensed Biological Materials.

  • New Technology When new or updated technology is introduced into a workplace, it will be the responsibility of the employer to provide appropriate and, if necessary, ongoing training to the employees directly affected. Such training will include any health and safety implications or information that will enable employees to operate the equipment without discomfort and will help maintain their general well-being.

  • Foreground IP This subparagraph d. shall not apply to unmodified commercial off‐the‐shelf goods. If Services or goods are developed, modified or redesigned pursuant to this Contract then the paragraphs below apply.

  • Background IP Each Party will own all right, title and interest in its Background IP.

  • Third Party Technology Customer is hereby notified that third parties have licensed certain technology to Company, which is contained in the Software. Notwithstanding anything herein to the contrary, Customer hereby consents to the disclosure of Customer’s identity, and such other terms of this Agreement as necessary, to such third party licensors for the purpose of enabling Company to comply with the terms and conditions of such third party licenses. Any such Customer information will be provided pursuant to an obligation of confidentiality and nondisclosure at least as stringent as that imposed by this Agreement.

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Joint Inventions For Subject Inventions conceived or first actually reduced to practice under this Agreement that are joint Subject Inventions made by CONTRACTOR and USER, each Party shall have the option to elect and retain title to its undivided rights in such joint Subject Inventions.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.